TY - JOUR T1 - Coinfection with <em>Strongyloides</em> and SARS-CoV-2: protocol for a systematic review JF - medRxiv DO - 10.1101/2023.01.30.23285219 SP - 2023.01.30.23285219 AU - Elena C Rosca AU - Carl Heneghan AU - Elizabeth A Spencer AU - Annette Plüddemann AU - Susanna Maltoni AU - Sara Gandini AU - Igho J Onakpoya AU - David H Evans AU - John M Conly AU - Tom Jefferson Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/31/2023.01.30.23285219.abstract N2 - Rationale for the review COVID-19 treatment can worsen parasitic disease in patients with coinfection. Consequently, there is a need to investigate the infection with SARS-CoV-2 and Strongyloides. We aim to systematically review clinical and laboratory features of COVID-19 and Strongyloides coinfection, to investigate possible interventions and outcomes in this pathology. Also, we aim to identify difficulties in managing the parasitic disease manifestations in this context and to emphasize research gaps requiring further attention.Methods We will search two electronic databases – LitCOVID, and WHO COVID-19 and will include studies on SARS-CoV-2 and Strongyloides coinfection. We will adapt the WHO-UMC system for standardized case causality assessment to evaluate if using corticosteroids or other immunosuppressive drugs in COVID-19 patients determined acute strongyloidiasis manifestations.Expected results We will present the evidence in three distinct packages: study description, methodological quality assessment and data extracted. We will summarize the evidence and will draw conclusions as to the quality of the evidence.Competing Interest StatementTJ disclosure is available here: https://restoringtrials.org CJH holds grant funding from the NIHR, the NIHR School for Primary Care Research, the NIHR BRC Oxford and the World Health Organization for a series of Living rapid reviews on the modes of transmission of SARs CoV 2, reference WHO registration No2020/1077093, and to carry out a scoping review of systematic reviews of interventions to improve vaccination uptake, reference WHO Registration 2021/1138353 0. He has received financial remuneration from an asbestos case and given legal advice on mesh and hormone pregnancy tests cases. He has received expenses and fees for his media work, including occasional payments from BBC Radio 4 Inside Health and The Spectator. He receives expenses for teaching EBM and is also paid for his GP work in NHS out of hours (contract Oxford Health NHS Foundation Trust). He has also received income from the publication of a series of toolkit books and appraising treatment recommendations in non NHS settings. He is the Director of CEBM, an NIHR Senior Investigator and an advisor to Collateral Global. DHE holds grant funding from the Canadian Institutes for Health Research and Li Ka Shing Institute of Virology relating to the development of Covid 19 vaccines and the Canadian Natural Science and Engineering Research Council concerning Covid 19 aerosol transmission. He is a recipient of World Health Organization and Province of Alberta funding which supports the provision of BSL3 based SARS CoV 2 culture services to regional investigators. He also holds public and private sector contract funding relating to the development of poxvirus based Covid 19 vaccines, SARS CoV 2 inactivation technologies, and serum neutralization testing. JMC holds grants from the Canadian Institutes for Health Research on acute and primary care preparedness for COVID 19 in Alberta, Canada and was the primary local Investigator for a Staphylococcus aureus vaccine study funded by Pfizer, for which all funding was provided only to the University of Calgary. He is a co investigator on a WHO funded study using integrated human factors and ethnography approaches to identify and scale innovative IPC guidance implementation supports in primary care with a focus on low resource settings and using drone aerial systems to deliver medical supplies and PPE to remote First Nations communities during the COVID 19 pandemic. He also received support from the Centers for Disease Control and Prevention (CDC) to attend an Infection Control Think Tank Meeting. He is a member and Chair of the WHO Infection Prevention and Control Research and Development Expert Group for COVID 19 and the WHO Health Emergencies Programme (WHE) Ad hoc COVID 19 IPC Guidance Development Group, both of which provide multidisciplinary advice to the WHO, for which no funding is received and from which no funding recommendations are made for any WHO contracts or grants. He is also a member of the Cochrane Acute Respiratory Infections Group. SM is a pharmacist working for the Italian National Health System since 2002 and a member of one of the three Institutional Review Boards of Emilia Romagna Region (Comitato Etico Area Vasta Emilia Centro) since 2018. AP holds grant funding from the NIHR School for Primary Care Research. IJO, EAS and ECR have no interests to disclose. SG is an epidemiologist biostatistician group leader at the European Institute of oncology in Milan (Italy) and holding a grant funded by the European Union s Horizon Europe Research and Innovation Programme under Grant Agreement No 101046016 (Eucare project: EUROPEAN COHORTS OF PATIENTS AND SCHOOLS TO ADVANCE RESPONSE TO EPIDEMICS). Funding StatementThis work is supported by the National Institute for Health Research School for Primary Care Research [Project 569] and by the University of Calgary. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -